Quantcast

Latest itraconazole Stories

2014-06-25 08:32:36

$1.5 million in proceeds to fund 2014 commencement of HPPI's clinical development program for repurposing the approved anti-fungal drug itraconazole for the treatment of cancer, initially for the treatment of Basal Cell Carcinoma Nevus Syndrome TAMPA, Fla. and SAN DIEGO, June 25, 2014 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with...

2014-05-14 08:29:43

NORTHBROOK, Ill., May 14, 2014 /PRNewswire/ -- Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain. http://photos.prnewswire.com/prnvar/20140416/84970 Previously announced topline data showed that the randomized, double-blind SECURE study met the primary objective of demonstrating non-inferiority of...

2014-01-08 12:28:08

Presentation to be held at Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square, San Francisco TAMPA, Fla. and SAN DIEGO, Jan. 8, 2014 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that its president and chief executive officer, Mr. Nicholas J. Virca, will present at the...

2009-09-02 06:09:00

BARCELONA, Spain, Sept. 2 /PRNewswire/ -- LIVALO (pitavastatin) may have the potential for fewer drug-drug interactions, versus other statins, as evidenced by a new study that evaluated the effects of itraconazole, an antifungal medication, on the pharmacokinetics of LIVALO in healthy volunteers. The data were presented by Kowa at the European Society of Cardiology (ESC) Congress in Barcelona, Spain. Many statins currently prescribed in the United States, such as atorvastatin and...

2009-07-07 11:25:00

CLEVELAND, July 7 /PRNewswire/ -- TREK Diagnostic Systems, a Magellan Biosciences business and premier provider of diagnostic systems and susceptibility products for microbiology labs, has received clearance from the U.S. Food and Drug Administration (FDA) to include caspofungin in its line of YeastOne susceptibility products. TREK will make the drug available on custom YeastOne formats, allowing clinicians to create the plate that best meets their requirements. The custom format complements...

2009-06-02 07:00:00

CORAL GABLES, Fla., June 2 /PRNewswire/ -- Stiefel Laboratories, Inc. announced the completion and analysis of a pivotal phase III clinical trial for Hyphanox(TM) (itraconazole) tablet. The 200 mg itraconazole tablet formulation was developed using the proprietary Meltrex(R) technology. This trial is the largest randomized controlled clinical study in onychomycosis ever undertaken. The study compared once-daily oral dosing of one 200 mg Hyphanox(TM) tablet to two 100 mg capsules of...

2008-12-29 10:08:37

Some patients with severe asthma who also have allergic sensitivity to certain fungi enjoy great improvements in their quality of life and on other measures after taking an antifungal drug, according to new research from The University of Manchester in England. The findings were reported in the first issue for January of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. "We knew that many people with severe asthma are sensitized to several airborne...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related